IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:		f:	Mueller	Confirmation No.:	1828			
Serial No.:			09/891,715	Art Unit:	3763			
Filed	d:		June 26, 2001	Examiner:	Stigell, Theodore J			
For:			METHOD AND APPARATUS FOR TREATING ISCHEMIC TISSUE INFORMATION DISCLOSE	Attorney Docket No.: JRE STATEMENT	10177-142-999			
P.O. I	missioner Box 1450 andria, V	\mathbf{c}	Patents 313-1450					
Sir:								
subjec	ded certai ct U.S. pa	in inf itent	ice with the duty of disclosure provise formation which the Examiner may complication. It is requested that the Extra to the examination of the application	onsider material to the examiner make this information.	nination of the			
1.	Enclos	Enclosures accompanying this Information Disclosure Statement are:						
	1a.	\boxtimes	A list of all patents, publications, applications, or other information submitted for consideration by the office.					
	1b.	o. A legible copy of:						
			Each publication or that portion which caused it to be listed on the PTO-1449;					
			For each cited pending unpublished including the claims, and any drawin application which caused it to be list directed to that portion that have been private PAIR system;	ng of the application, or po ted on the PTO-1449 include	rtion of the ding any claims			
			An English language copy of search application or PCT International Sea	report(s) from a counterpaarch Report;	rt foreign			
			Explanations of relevancy (ATTAC abstracts of the non-English language		nglish language			
			All other information or portion whi	ich caused it to be listed on	the PTO-1449.			
	lc.	\boxtimes	Pursuant to 37 C.F.R. § 1.98(a)(2)(2) patent application publications are no office.					
	ld.		Pursuant to 1287 OG 163, copies of are available at the USPTO's private					
2	П	Th	is Information Disclosure Statement i	s filed under 37 C F.R. 81	97(b):			

		Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);					
		Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;					
		☐ Before the mailing of the first Office action on the merits;					
		Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.					
3.	under 3	This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the specified in 37 C.F.R §1.97(b), but before the mailing date of any of a final action 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that ise closes prosecution in the application.					
(Check either Item 3a or 3b)							
	3a.	☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.					
	3b.	The \$180.00 fee set forth in 37 C.F.R. \$1.17(p) in accordance with 37 C.F.R. \$1.97(c) is:					
		☐ enclosed.☒ to be charged to Jones Day Deposit Account No. 50-3013.					
		(Item 3b to be checked if any reference known for more than 3 months)					
4.	period	This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.					
	The Ce	he Certification Statement in Item 5 below is applicable.					
		The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is: — enclosed.					
		to be charged to Jones Day Deposit Account No. 50-3013.					
5.		Certification Statement (applicable if Item 3a or Item 4 is checked):					
		(Check either Item 5a or 5b)					
	5a.	In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.					
	5b.	Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.					
	5c.	Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.					

6.		This application is a continuation application under 37 C.F.R. §1.53(b) or (d)					
	(Check appropriate Items 6a, 6b and/or 6c)						
	6a.	6a. A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrer filed herewith.					
	6b.	No. , filed on	ns listed on Form PTO-1449 from prior , of which this application claims being submitted pursuant to 37 C.F.R.	priority under 35			
	6c.	Copies of the publication Ser	nations listed on Form PTO-1449 were n ial No. , filed on , and are p	ot previously cited in provided herewith.			
7.		This is a Supplemental I	nformation Disclosure Statement. (Che	ck Item 7a)			
	7a.	supplements the Info attempt was made to were made. These o additional time is rec	nformation Disclosure Statement under ormation Disclosure Statement filed on comply with 37 C.F.R. §1.98, but inadmissions have been corrected herein. A quested so that this Supplemental Infornasidered as if properly filed on	. A bona fide vertent omissions accordingly,			
8.	In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:						
(Check Item 8a, 8b, or 8c)							
	8a. Satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.						
	8b.	Set forth in the appli	the application.				
	8c.	☐ Enclosed as an attack	hment hereto.				
9.	The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 50-3013.						
10.	No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).						
Date:	December 18, 2007		Respectfully submitted, Lingth D. Cafall Kenneth S. Canfield For: Gidon D. Stern JONES DAY 222 East 41st Street New York, New York 10017-6702 (212) 326-3939	58,442 (Reg. No.) (Reg. No. 27,469)			